SOPH Market Analysis

Overview

Fundamentals

P/E ratio
EPS (TTM)$-1.170.0% YoY
Profit margin-102.2%HEALTHCARE
Market cap$381.3MSmall cap

Wall Street coverage

$8.00median target· current $5.05 (+58.4%)4 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E
PEG ratio
P/B
8.09
P/S (TTM)
4.93
EV/EBITDA
-0.30

Profitability & growth

ROE (TTM)
-110.0%
Operating margin
-85.4%
Revenue growth YoY
22.4%
Dividend yield
Beta
1.01
Last earnings
Mar 3, 2026 · Estimate $-0.22 · Reported $-0.17
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Sophia Genetics SA

Sophia Genetics SA (SOPH) is a trailblazer in data-driven medicine, specializing in advanced genomic and clinical data analytics aimed at improving patient outcomes. Leveraging state-of-the-art machine learning algorithms, the company offers a robust platform that empowers hospitals and laboratories to decode complex genomic information, thereby enabling personalized treatment approaches, particularly in oncology, rare diseases, and hereditary conditions. With a strong global presence and strategic alliances with leading healthcare institutions, Sophia Genetics is dedicated to revolutionizing…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
LA PIECE 12, ROLLE, SWITZERLAND
Fiscal year end
December
Latest quarter
Dec 31, 2025
Market cap$381.3M
Shares outstanding$71.7M
52W high$5.70
52W low$2.59

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer